review and network meta-analysis. BMC Med. 2017 Oct 30;15(1):193. \[[PMC free article: PMC5662096](/pmc/articles/PMC5662096/)\] \[[PubMed: 29082855](https://pubmed.ncbi.nlm.nih.gov/29082855)\] 37. Ramos-Esquivel A, van der Laat A, Rojas-Vigott R, Juárez M, Corrales-Rodríguez L. Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open. 2017;2(3):e000236. \[[PMC free article: PMC5699523](/pmc/articles/PMC5699523/)\] \[[PubMed: 29181191](https://pubmed.ncbi.nlm.nih.gov/29181191)\] 38. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P., Members of IASLC Staging Committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009 May;4(5):568-77. \[[PubMed: 19357537](https://pubmed.ncbi.nlm.nih.gov/19357537)\] 39. Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S., Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015 Aug;26(8):1573-88. \[[PubMed: 25897013](https://pubmed.ncbi.nlm.nih.gov/25897013)\] 40. Lizama C, Slavova-Azmanova NS, Phillips M, Trevenen ML, Li IW, Johnson CE. Implementing Endobronchial Ultrasound-Guided (EBUS) for Staging and Diagnosis of Lung Cancer: A Cost Analysis. Med Sci Monit. 2018 Jan 29;24:582-589. \[[PMC free article: PMC5800486](/pmc/articles/PMC5800486/)\] \[[PubMed: 29377878](https://pubmed.ncbi.nlm.nih.gov/29377878)\] 41. Bugalho A, de Santis M, Slubowski A, Rozman A, Eberhardt R. Trans-esophageal endobronchial ultrasound-guided needle aspiration (EUS-B-NA): A road map for the chest physician. Pulmonology. 2018 Jan/Feb;24(1):32-41. \[[PubMed: 29242047](https://pubmed.ncbi.nlm.nih.gov/29242047)\] 42. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005 Jan 01;23(1):175-83. \[[PubMed: 15625371](https://pubmed.ncbi.nlm.nih.gov/15625371)\] 43. D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012 Dec;7(12):1815-1822. \[[PubMed: 23154553](https://pubmed.ncbi.nlm.nih.gov/23154553)\] 44. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P., International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol. 2008 May;3(5):457-66. \[[PubMed: 18448996](https://pubmed.ncbi.nlm.nih.gov/18448996)\] 45. Tammemägi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley